Literature DB >> 10064231

Potential advantages of DNA immunization for influenza epidemic and pandemic planning.

R G Webster1.   

Abstract

Immunization with purified DNA is a powerful technique for inducing immune responses. The concept of DNA immunization involves insertion of the gene encoding the antigen of choice into a bacterial plasmid and injection of the plasmid into the host where the antigen is expressed and where it induces humoral and cellular immunity. The most effective routes and methods for DNA immunization are bombardment with particles coated with DNA ("gene gun" technique), followed by the intramuscular and intradermal routes. DNA immunization technology has the potential to induce immunity to all antigens that can be completely encoded in DNA, which therefore include all protein, but not carbohydrate, antigens. DNA immunization results in presentation of antigens to the host's immune system in a natural form, like that achieved with live-attenuated vaccines. The DNA immunization strategy has the potential to rapidly provide a new vaccine in the face of an emerging influenza pandemic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064231     DOI: 10.1086/515123

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

2.  Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.

Authors:  Lu Zhang; Na Jia; Jun Li; Yaping Han; Wuchun Cao; Shixia Wang; Zuhu Huang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.

Authors:  Lea Torrieri-Dramard; Bénédicte Lambrecht; Helena Lage Ferreira; Thierry Van den Berg; David Klatzmann; Bertrand Bellier
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

4.  Infectivity-enhancing antibodies to Ebola virus glycoprotein.

Authors:  A Takada; S Watanabe; K Okazaki; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens.

Authors:  Chang-Won Lee; Dennis A Senne; David L Suarez
Journal:  Clin Vaccine Immunol       Date:  2006-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.